Iambic Therapeutics (NASDAQ:IAM – Get Free Report) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.
Iambic Therapeutics Trading Down 12.6%
Shares of Iambic Therapeutics stock opened at $10.17 on Friday. Iambic Therapeutics has a 1 year low of $9.60 and a 1 year high of $25.00.
Insider Transactions at Iambic Therapeutics
In other news, Director Evan Lockwood Rachlin acquired 718,750 shares of Iambic Therapeutics stock in a transaction that occurred on Friday, October 16th. The stock was purchased at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the completion of the transaction, the director owned 2,588,248 shares in the company, valued at approximately $41,411,968. This trade represents a 38.45% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 22.90% of the company’s stock.
About Iambic Therapeutics
Read More
- Five stocks we like better than Iambic Therapeutics
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
